There are probably few health care professionals who are unaware of the concerns about the apparent overprescription of opioids. However, we have had only limited information on how good a job physicians may actually be doing in prescribing these medications.
(ACR2014) Top picks from RheumatologyNetwork Editorial Board members. Nancy Lane MD liked a mouse study that inquires why so many arthritis patients continue to experience pain despite rheumatology's success at conquering inflammation.
Movantik (naloxegol), taken once daily, blocks opioid receptors in the gut but does not cross the blood-brain barrier to affect opioid analgesia. It is expected to be available sometime in the first half of 2015.